Ultrahypofractionated Radiotherapy for Localised Prostate Cancer: How Far Can We Go?
Author:
Publisher
Elsevier BV
Subject
Radiology, Nuclear Medicine and imaging,Oncology
Reference80 articles.
1. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG Oncology RTOG 0126 randomized clinical trial;Michalski;JAMA Oncol,2018
2. Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single institution randomized clinical trial;Pasalic;Int J Radiat Oncol Biol Phys,2019
3. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer;Catton;J Clin Oncol,2017
4. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial;Dearnaley;Lancet Oncol,2016
5. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial;Widmark;Lancet,2019
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Review of Current Treatment Intensification Strategies for Prostate Cancer Patients;Cancers;2023-11-28
2. Every-Other-Day Versus Once-a-Week Urethra-Sparing Prostate Stereotactic Body Radiation Therapy: 5-Year Results of a Randomized Phase 2 Trial;International Journal of Radiation Oncology*Biology*Physics;2023-11
3. Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancer;Radiotherapy and Oncology;2023-11
4. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer: more than a simple “MIRAGE”?;Translational Cancer Research;2023-10
5. State of the art and future challenges of urethra-sparing stereotactic body radiotherapy for prostate cancer: a systematic review of literature;World Journal of Urology;2023-09-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3